Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study

2005 ◽  
Vol 47 (1) ◽  
pp. 10-17 ◽  
Author(s):  
Joachim Klisch ◽  
Ralf Kubalek ◽  
Kai M. Scheufler ◽  
Ute Zirrgiebel ◽  
Joachim Drevs ◽  
...  
2016 ◽  
Vol 01 (01) ◽  
Author(s):  
Hala Abdel Dayem Mohamed ◽  
Howyada Sayed Abd El All ◽  
Amr Abd El Aziz Kamel ◽  
Wagdy Talaat Yossef ◽  
Makram Mohamed Hammam

2002 ◽  
Vol 152 (9-10) ◽  
pp. 223-225 ◽  
Author(s):  
C. Goldberger ◽  
J. Dulak ◽  
C. Duftner ◽  
F. Weidinger ◽  
A. Falkenbach ◽  
...  

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247161
Author(s):  
Ameay V. Naravane ◽  
Rusdeep Mundae ◽  
Yujia Zhou ◽  
Christopher Santilli ◽  
Frederik J. G. M. van Kuijk ◽  
...  

Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (RVO). This study aims to assess the effect of unintended delays in anti-VEGF treatment during the first wave of the COVID-19 pandemic. This retrospective case series identified patients receiving regularly scheduled anti-VEGF intravitreal injections based on current procedural terminology (CPT) code at two practices in Minnesota. Diagnoses were limited to nAMD, diabetic macular edema (DME), proliferative diabetic retinopathy, and RVO. Patients were divided into two groups based on whether they maintained or delayed their follow-up visit by more than two weeks beyond the recommended treatment interval during the COVID-19 lockdown. The ‘COVID-19 lockdown’ was defined as the period after March, 28th, 2020, when a lockdown was declared in Minnesota. We then compared the visual acuity and structural changes to the retina using ocular coherence tomography (OCT) to assess whether delayed treatment resulted in worse visual outcomes. A total of 167 eyes from 117 patients met criteria for inclusion in this study. In the delayed group, the average BCVA at the pre- and post-lockdown visits were 0.614 and 0.715 (logMAR) respectively (p = 0.007). Central subfield thickness (CST) increased from 341 to 447 in the DME delayed group (p = 0.03) while the CST increased from 301 to 314 (p = 0.4) in the nAMD delayed group. The results of this pilot study suggests that treatment delays may have a negative impact on the visual and anatomic outcomes of patients with nAMD and DME. Future studies with larger sample sizes are required for further investigation.


2007 ◽  
Vol 75 (1) ◽  
pp. A17
Author(s):  
E.G. Barreiro ◽  
L. Pietro ◽  
R. Mattar ◽  
D.C. Damasceno ◽  
I.M.P. Calderon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document